Teaching an old dog new tricks: Drug repositioning in small cell lung cancer

Cancer Discovery

Volumn 3, Issue 12, 2013, Pages 1333-1335

  Wang, Jing ^a   Byers, Lauren Averett ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BEPRIDIL; CALCIUM; CASPASE 3; CISPLATIN; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR; IMIPRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC RECEPTOR; NEUROPEPTIDE; PROMETHAZINE; SEROTONIN 2 RECEPTOR; THALIDOMIDE;

ARTICLE; DRUG REPOSITIONING; GENE EXPRESSION; HUMAN; LIMB MALFORMATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTINEOPLASTIC AGENTS; DRUG REPOSITIONING; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; RECEPTORS, G-PROTEIN-COUPLED; SMALL CELL LUNG CARCINOMA;

EID: 84890012785     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0790     Document Type: Article

References (11)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
2. Recalcitrant Cancer Research Act of 2012. Pub. L. No. 112-239, Sect. 1083 (Jan 2, 2013).
3. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013;3:1364-77.
4. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011; 3: 96ra76.
5. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77.
6. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2: 798-811.
7. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013; 93: 335-41.
8. Collins F. Francis Collins: we need better drugs-now. TED Talks. 2012. Available from: http://www.ted.com/talks/francis_collins_we_ need_better_drugs_now.html (accessed October 22, 2013).
9. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
10. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013 Sep 15. [Epub ahead of print].
11. Teicher BA. Perspective: opportunities in recalcitrant, rare and neglected tumors. Oncol Rep 2013; 30: 1030-4